News Headlines

  1. KinderPharm LLC And Worldwide Clinical Trials Form Strategic Alliance
    4/17/2018

    KinderPharm LLC, dedicated exclusively to pediatric clinical research, and Worldwide Clinical Trials Inc. (Worldwide), an award-winning, full-service CRO, today announced they have entered into a strategic alliance to deliver the world’s first single center of excellence for pediatric drug development and clinical research for the pharmaceutical industry.

  2. Pioneering Clinical Practice Live Implementation Proves Effectiveness Of Medial EarlySign's AI-Based Tool To Identify Patients At High Risk Of Having Colorectal Cancer
    4/17/2018

    Medial EarlySign (www.earlysign.com), a leader in machine-learning (ML) based solutions to improve disease management, today announced the publication of successful results for the live, physician-supported implementation of its solution for aiding in earlier colorectal cancer detection, in new research published by the Journal of Oncology CCI.

  3. Biothera Pharmaceuticals Presents Translational Data From Ongoing Clinical Trials Showing Imprime PGG In Combination With Merck’s KEYTRUDA® (Pembrolizumab) Drives Innate And Adaptive Immune Responses In Tumors
    4/16/2018

    Biothera Pharmaceuticals, Inc. today announced the presentation of new translational data from ongoing phase 2 clinical trials combining Biothera’s Imprime PGG with KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy marketed by Merck (known as MSD outside the United States and Canada).

  4. New Preclinical Studies Reinforce The Potential For Heightened Anti-Cancer Activity Of Combination Therapies Based On Immunovaccine’s Proprietary Delivery Platform
    4/16/2018

    Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that it presented new research on its T-cell activating platform at the American Association for Cancer Research (AACR) Annual Meeting 2018.

  5. G1 Therapeutics Announces Initiation Of Phase 1b/2 Clinical Trial Of G1T38 In Combination With Tagrisso For EGFR-Mutant Non-Small Cell Lung Cancer
    4/16/2018

    G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that it has initiated a Phase 1b/2 clinical trial assessing G1T38, its oral CDK4/6 inhibitor, in combination with Tagrisso® (osimertinib) in people with EGFR-mutant (EGFRm) non-small cell lung cancer (NSCLC).

  6. Idera Pharmaceuticals Enters Into A Clinical Development Support Agreement With Pillar Partners Foundation To Expand The Clinical Research On IMO-2125 Beyond PD-1 Refractory Melanoma
    4/16/2018

    Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel oligonucleotide therapeutics for oncology and rare diseases, today announced it has entered into a clinical development support agreement with Pillar Partners Foundation (“Pillar Partners”).

  7. Deerfield Leads Investment Of Up To $50M In Sollis Therapeutics' Innovative Solution For Sciatica Pain
    4/12/2018

    Deerfield Management and Sollis Therapeutics today announced a Deerfield-led investment of up to $50 million in Sollis Therapeutics. The investment will support the development of an innovative non-opioid and non-steroid solution for pain associated with sciatica and other neuropathic pain syndromes.

  8. GSK Signs Strategic Agreement To Transfer Rare Disease Gene Therapy Portfolio To Orchard Therapeutics
    4/12/2018

    GSK and Orchard Therapeutics today announced a strategic agreement, under which GSK will transfer its portfolio of approved and investigational rare disease gene therapies to Orchard, securing the continued development of the programmes and access for patients.

  9. Catalent Completes $5.5M Expansion Of Clinical Storage At Philadelphia Facility
    4/12/2018

    Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, recently announced it has completed a $5.5M expansion program at its 200,000+ square foot Philadelphia, Pennsylvania, site to provide additional clinical packaging and storage capacity.

  10. Bioclinica Announces Executive Hires And Promotion
    4/11/2018

    Bioclinica®, the world-leading provider of scientific- and technology-enabled solutions for clinical research, recently announces two executive-level additions and one promotion, further strengthening and diversifying its executive leadership team.